



an Open Access Journal by MDPI

Impact Factor 3.0

CiteScore 7.1

Indexed in PubMed

Antibodies



[mdpi.com/
journal/
antibodies](https://mdpi.com/journal/antibodies)



Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Editor-in-Chief

Prof. Dr. Arne Skerra

Aims

Antibodies publishes research articles, reviews, communications and short notes in all areas related to antibodies. A major focus is studies translating basic research to applications, including development of therapeutic antibodies and especially human monoclonal antibodies. However, any other study on basic and translational research related to antibodies is welcome. Original studies should be published with as much detail as possible especially the methods and materials.

Scope

This journal covers all topics related to antibodies and antigens. Major topics of interest include (but are not limited to):

- Antibodies and the humoral immune response
- Discovery, generation and selection of antibodies
- Antibody structure and function
- Antibody engineering, conjugates and fusion proteins
- Antibodies in biomedical research and therapy

Author Benefits

Open Access

Unlimited and free access for readers

No Copyright Constraints

Retain copyright of your work and free use of your article

Thorough Peer-Review

Discounts on Article Processing Charges (APC)

If you belong to an institute that participates with the MDPI Institutional Open Access Program

No Space Constraints, No Extra Space or Color Charges

No restriction on the maximum length of the papers, number of figures or colors

Journal Rank

CiteScore - Q2 (*Drug Discovery*)

Coverage by Leading Indexing Services

Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases

Rapid Publication

A first decision is provided to authors approximately 23 days after submission; acceptance to publication is undertaken in 6.6 days (median values for papers published in this journal in the first half of 2024)

MDPI is a member of

CASPA



STM¹

| C | O | P | E |

SPARC*
Europe

U | K | S | G



DOAJ



ORCID



Editorial Office

antibodies@mdpi.com

MDPI

Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

mdpi.com

July 2024

